Negative feedback regulation of AXL by miR-34a modulates apoptosis in lung cancer cells

RNA

Volumn 22, Issue 2, 2016, Pages 303-315

  Cho, Chun Yu ^a,b   Huang, Jhy Shrian ^a,c,d   Shiah, Shine Gwo ^a   Chung, Shih Ying ^a   Lay, Jong Ding ^e   Yang, Ya Yu ^a   Lai, Gi Ming ^a,c,f   Cheng, Ann Lii ^a,g   Chen, Li Tzong ^a   Chuang, Shuang En ^a,b  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b NATIONAL CENTRAL UNIVERSITY   (Taiwan)

^c TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^d I SHOU UNIVERSITY   (Taiwan)

^e NATIONAL TAICHUNG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

^f TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^g NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Apoptosis; AXL; ELK1; Feedback loop regulation; JNK; MiR 34a

Indexed keywords

AXL PROTEIN TYROSINE KINASE; MESSENGER RNA; MICRORNA 34A; PROTEIN TYROSINE KINASE; STRESS ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR ELK 1; UNCLASSIFIED DRUG; AXL RECEPTOR TYROSINE KINASE; ELK1 PROTEIN, HUMAN; MICRORNA; MIRN34 MICRORNA, HUMAN; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; ONCOPROTEIN; PROTEIN BINDING; TYROSINE;

3' UNTRANSLATED REGION; APOPTOSIS; ARTICLE; AUTOPHOSPHORYLATION; AUTOREGULATION; BIOINFORMATICS; DOWN REGULATION; HUMAN; HUMAN CELL; LUNG CANCER; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; BINDING SITE; EPITHELIUM CELL; GENE EXPRESSION REGULATION; GENETICS; LUNG; METABOLISM; MICROARRAY ANALYSIS; PATHOLOGY; PHOSPHORYLATION; PHYSIOLOGICAL FEEDBACK; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

APOPTOSIS; BINDING SITES; CELL LINE, TUMOR; EPITHELIAL CELLS; ETS-DOMAIN PROTEIN ELK-1; FEEDBACK, PHYSIOLOGICAL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LUNG; MAP KINASE KINASE 4; MICROARRAY ANALYSIS; MICRORNAS; PHOSPHORYLATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS; RECEPTOR PROTEIN-TYROSINE KINASES; SIGNAL TRANSDUCTION; TYROSINE;

EID: 84956826470     PISSN: 13558382     EISSN: 14699001     Source Type: Journal    
DOI: 10.1261/rna.052571.115     Document Type: Article

References (62)

1. Acunzo M, Romano G, Palmieri D, Lagana A, Garofalo M, Balatti V, Drusco A, Chiariello M, Nana-Sinkam P, Croce CM. 2013. Crosstalk between MET and EGFR in non-small cell lung cancer involves miR-27a and Sprouty2. Proc Natl Acad Sci 110: 8573-8578.
2. Bartel DP. 2004. MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell 116: 281-297.
3. Bellosta P, Costa M, Lin DA, Basilico C. 1995. The receptor tyrosine kinase ARK mediates cell aggregation by homophilic binding. Mol Cell Biol 15: 614-625.
4. Boysen J, Sinha S, Price-Troska T, Warner SL, Bearss DJ, Viswanatha D, Shanafelt TD, Kay NE, Ghosh AK. 2014. The tumor suppressor axis p53/miR-34a regulates Axl expression in B-cell chronic lymphocytic leukemia: Implications for therapy in p53-defective CLL patients. Leukemia 28: 451-455.
5. Cahill S, Smyth P, Finn SP, Denning K, Flavin R, O'Regan EM, Li J, Potratz A, Guenther SM, Henfrey R, et al. 2006. Effect of ret/PTC 1 rearrangement on transcription and post-Transcriptional regulation in a papillary thyroid carcinoma model. Mol Cancer 5: 70.
6. Cavigelli M, Dolfi F, Claret FX, Karin M. 1995. Induction of c-fos expression through JNK-mediated TCF/Elk-1 phosphorylation. EMBO J 14: 5957-5964.
7. Chang TC, Wentzel EA, Kent OA, Ramachandran K, Mullendore M, Lee KH, Feldmann G, Yamakuchi M, Ferlito M, Lowenstein CJ, et al. 2007. Transactivation of miR-34a by p53 broadly influences gene expression and promotes apoptosis. Mol Cell 26: 745-752.
8. Chou YT, Lin HH, Lien YC, Wang YH, Hong CF, Kao YR, Lin SC, Chang YC, Lin SY, Chen SJ, et al. 2010. EGFR promotes lung tumorigenesis by activating miR-7 through a Ras/ERK/Myc pathway that targets the Ets2 transcriptional repressor ERF. Cancer Res 70: 8822-8831.
9. Christoffersen NR, Shalgi R, Frankel LB, Leucci E, Lees M, Klausen M, Pilpel Y, Nielsen FC, Oren M, Lund AH. 2010. p53-independent upregulation of miR-34a during oncogene-induced senescence represses MYC. Cell Death Differ 17: 236-245.
10. Chung BI, Malkowicz SB, Nguyen TB, Libertino JA, McGarvey TW. 2003. Expression of the proto-oncogene Axl in renal cell carcinoma. DNA Cell Biol 22: 533-540.
11. Corney DC, Hwang CI, Matoso A, Vogt M, Flesken-Nikitin A, Godwin AK, Kamat AA, Sood AK, Ellenson LH, Hermeking H, et al. 2010. Frequent downregulation of miR-34 family in human ovarian cancers. Clin Cancer Res 16: 1119-1128.
12. Craven RJ, Xu LH, Weiner TM, Fridell YW, Dent GA, Srivastava S, Varnum B, Liu ET, Cance WG. 1995. Receptor tyrosine kinases expressed in metastatic colon cancer. Int J Cancer 60: 791-797.
13. Demarchi F, Verardo R, Varnum B, Brancolini C, Schneider C. 2001. Gas6 anti-Apoptotic signaling requires NF-?B activation. J Biol Chem 276: 31738-31744.
14. Dutta KK, Zhong Y, Liu YT, Yamada T, Akatsuka S, Hu Q, Yoshihara M, Ohara H, Takehashi M, Shinohara T, et al. 2007. Association of microRNA-34a overexpression with proliferation is cell type-dependent. Cancer Sci 98: 1845-1852.
15. Esquela-Kerscher A, Slack FJ. 2006. Oncomirs-microRNAs with a role in cancer. Nat Rev Cancer 6: 259-269.
16. Fridell YW, Jin Y, Quilliam LA, Burchert A, McCloskey P, Spizz G, Varnum B, Der C, Liu ET. 1996. Differential activation of the Ras/extracellular-signal-regulated protein kinase pathway is responsible for the biological consequences induced by the Axl receptor tyrosine kinase. Mol Cell Biol 16: 135-145.
17. Gallicchio M, Mitola S, Valdembri D, Fantozzi R, Varnum B, Avanzi GC, Bussolino F. 2005. Inhibition of vascular endothelial growth factor receptor 2-mediated endothelial cell activation by Axl tyrosine kinase receptor. Blood 105: 1970-1976.
18. Georgescu MM, Kirsch KH, Shishido T, Zong C, Hanafusa H. 1999. Biological effects of c-Mer receptor tyrosine kinase in hematopoietic cells depend on the Grb2 binding site in the receptor and activation of NF-?B. Mol Cell Biol 19: 1171-1181.
19. Hafizi S, Ibraimi F, Dahlbäck B. 2005. C1-TEN is a negative regulator of the Akt/PKB signal transduction pathway and inhibits cell survival, proliferation, and migration. FASEB J 19: 971-973.
20. Hasanbasic I, Cuerquis J, Varnum B, Blostein MD. 2004. Intracellular signaling pathways involved in Gas6-Axl-mediated survival of endothelial cells. Am J Physiol Heart Circ Physiol 287: H1207-H1213.
21. Heiring C, Dahlback B, Muller YA. 2004. Ligand recognition and homophilic interactions in Tyro3: Structural insights into the Axl/Tyro3 receptor tyrosine kinase family. J Biol Chem 279: 6952-6958.
22. Hermeking H. 2010. The miR-34 family in cancer and apoptosis. Cell Death Differ 17: 193-199.
23. Hong CC, Lay JD, Huang JS, Cheng AL, Tang JL, Lin MT, Lai GM, Chuang SE. 2008. Receptor tyrosine kinase AXL is induced by chemotherapy drugs and overexpression of AXL confers drug resistance in acute myeloid leukemia. Cancer Lett 268: 314-324.
24. Huang JS, Cho CY, Hong CC, Yan MD, Hsieh MC, Lay JD, Lai GM, Cheng AL, Chuang SE. 2013. Oxidative stress enhances Axl-mediated cell migration through an Akt1/Rac1-dependent mechanism. Free Radic Biol Med 65: 1246-1256.
25. John B, Enright AJ, Aravin A, Tuschl T, Sander C, Marks DS. 2004. Human MicroRNA targets. PLoS Biol 2: E363.
26. Kaller M, Liffers ST, Oeljeklaus S, Kuhlmann K, Roh S, Hoffmann R, Warscheid B, Hermeking H. 2011. Genome-wide characterization of miR-34a induced changes in protein and mRNA expression by a combined pulsed SILAC and microarray analysis. Mol Cell Proteomics doi: 10.1074/mcp.M111.010462.
27. Kefas B, Godlewski J, Comeau L, Li Y, Abounader R, Hawkinson M, Lee J, Fine H, Chiocca EA, Lawler S, et al. 2008. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res 68: 3566-3572.
28. Lay JD, Hong CC, Huang JS, Yang YY, Pao CY, Liu CH, Lai YP, Lai GM, Cheng AL, Su IJ, et al. 2007. Sulfasalazine suppresses drug resistance and invasiveness of lung adenocarcinoma cells expressing AXL. Cancer Res 67: 3878-3887.
29. Lee WP, Wen Y, Varnum B, Hung MC. 2002. Akt is required for Axl-Gas6 signaling to protect cells from E1A-mediated apoptosis. Oncogene 21: 329-336.
30. Lee JH, Voortman J, Dingemans AM, Voeller DM, Pham T, Wang Y, Giaccone G. 2011. MicroRNA expression and clinical outcome of small cell lung cancer. PLoS One 6: E21300.
31. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. 2003. Prediction of mammalian microRNA targets. Cell 115: 787-798.
32. Li LC, Okino ST, Zhao H, Pookot D, Place RF, Urakami S, Enokida H, Dahiya R. 2006. Small dsRNAs induce transcriptional activation in human cells. Proc Natl Acad Sci 103: 17337-17342.
33. Li N, Fu H, Tie Y, Hu Z, Kong W, Wu Y, Zheng X. 2009a. miR-34a inhibits migration and invasion by down-regulation of c-Met expression in human hepatocellular carcinoma cells. Cancer Lett 275: 44-53.
34. Li Y, Guessous F, Zhang Y, Dipierro C, Kefas B, Johnson E, Marcinkiewicz L, Jiang J, Yang Y, Schmittgen TD, et al. 2009b. MicroRNA-34a inhibits glioblastoma growth by targeting multiple oncogenes. Cancer Res 69: 7569-7576.
35. Lizé M, Pilarski S, Dobbelstein M. 2010. E2F1-inducible microRNA 449a/b suppresses cell proliferation and promotes apoptosis. Cell Death Differ 17: 452-458.
36. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H, Knyazev P, Diebold J, Hermeking H. 2008. Inactivation of miR-34a by aberrant CpG methylation in multiple types of cancer. Cell Cycle 7: 2591-2600.
37. Lujambio A, Lowe SW. 2012. The microcosmos of cancer. Nature 482: 347-355.
38. Ma Y, Qin H, Cui Y. 2013. MiR-34a targets GAS1 to promote cell proliferation and inhibit apoptosis in papillary thyroid carcinoma via PI3K/Akt/Bad pathway. Biochem Biophys Res Commun 441: 958-963.
39. Mackiewicz M, Huppi K, Pitt JJ, Dorsey TH, Ambs S, Caplen NJ. 2011. Identification of the receptor tyrosine kinase AXL in breast cancer as a target for the human miR-34a microRNA. Breast Cancer Res Treat 130: 663-679.
40. Meric F, Lee WP, Sahin A, Zhang H, Kung HJ, Hung MC. 2002. Expression profile of tyrosine kinases in breast cancer. Clin Cancer Res 8: 361-367.
41. Migliore C, Petrelli A, Ghiso E, Corso S, Capparuccia L, Eramo A, Comoglio PM, Giordano S. 2008. MicroRNAs impair MET-mediated invasive growth. Cancer Res 68: 10128-10136.
42. Mudduluru G, Vajkoczy P, Allgayer H. 2010. Myeloid zinc finger 1 induces migration, invasion, and in vivo metastasis through Axl gene expression in solid cancer. Mol Cancer Res 8: 159-169.
43. Mudduluru G, Ceppi P, Kumarswamy R, Scagliotti GV, Papotti M, Allgayer H. 2011. Regulation of Axl receptor tyrosine kinase expression by miR-34a and miR-199a/b in solid cancer. Oncogene 30: 2888-2899.
44. O'Bryan JP, Frye RA, Cogswell PC, Neubauer A, Kitch B, Prokop C, Espinosa R III, Le Beau MM, Earp HS, Liu ET. 1991. axl, a transforming gene isolated from primary human myeloid leukemia cells, encodes a novel receptor tyrosine kinase. Mol Cell Biol 11: 5016-5031.
45. Ott M, Litzenburger UM, Sahm F, Rauschenbach KJ, Tudoran R, Hartmann C, Marquez VE, von Deimling A, Wick W, Platten M. 2012. Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase. PLoS One 7: E47663.
46. Place RF, Li LC, Pookot D, Noonan EJ, Dahiya R. 2008. MicroRNA-373 induces expression of genes with complementary promoter sequences. Proc Natl Acad Sci 105: 1608-1613.
47. Raver-Shapira N, Marciano E, Meiri E, Spector Y, Rosenfeld N, Moskovits N, Bentwich Z, Oren M. 2007. Transcriptional activation of miR-34a contributes to p53-mediated apoptosis. Mol Cell 26: 731-743.
48. Reddy SD, Ohshiro K, Rayala SK, Kumar R. 2008. MicroRNA-7, a homeobox D10 target, inhibits p21-Activated kinase 1 and regulates its functions. Cancer Res 68: 8195-8200.
49. Rochlitz C, Lohri A, Bacchi M, Schmidt M, Nagel S, Fopp M, Fey MF, Herrmann R, Neubauer A. 1999. Axl expression is associated with adverse prognosis and with expression of Bcl-2 and CD34 in de novo acute myeloid leukemia (AML): Results from a multicenter trial of the Swiss Group for Clinical Cancer Research (SAKK). Leukemia 13: 1352-1358.
50. Sainaghi PP, Castello L, Bergamasco L, Galletti M, Bellosta P, Avanzi GC. 2005. Gas6 induces proliferation in prostate carcinoma cell lines expressing the Axl receptor. J Cell Physiol 204: 36-44.
51. Shieh Y-S, Lai C-Y, Kao Y-R, Shiah S-G, Chu Y-W, Lee H-S, Wu C-W. 2005. Expression of axl in lung adenocarcinoma and correlation with tumor progression. Neoplasia 7: 1058-1064.
52. Tsai LH, Chen PM, Cheng YW, Chen CY, Sheu GT, Wu TC, Lee H. 2014. LKB1 loss by alteration of the NKX2-1/p53 pathway promotes tumor malignancy and predicts poor survival and relapse in lung adenocarcinomas. Oncogene 33: 3851-3860.
53. Vogt M, Munding J, Grüner M, Liffers ST, Verdoodt B, Hauk J, Steinstraesser L, Tannapfel A, Hermeking H. 2011. Frequent concomitant inactivation of miR-34a and miR-34b/c by CpG methylation in colorectal, pancreatic, mammary, ovarian, urothelial, and renal cell carcinomas and soft tissue sarcomas. Virchows Arch 458: 313-322.
54. Webster RJ, Giles KM, Price KJ, Zhang PM, Mattick JS, Leedman PJ. 2009. Regulation of epidermal growth factor receptor signaling in human cancer cells by microRNA-7. J Biol Chem 284: 5731-5741.
55. Whitmarsh AJ, Shore P, Sharrocks AD, Davis RJ. 1995. Integration of MAP kinase signal transduction pathways at the serum response element. Science 269: 403-407.
56. Wimmel A, Glitz D, Kraus A, Roeder J, Schuermann M. 2001. Axl receptor tyrosine kinase expression in human lung cancer cell lines correlates with cellular adhesion. Eur J Cancer 37: 2264-2274.
57. Wu CW, Li AF, Chi CW, Lai CH, Huang CL, Lo SS, Lui WY, Lin WC. 2002. Clinical significance of AXL kinase family in gastric cancer. Anticancer Res 22: 1071-1078.
58. Wu YM, Robinson DR, Kung HJ. 2004. Signal pathways in up-regulation of chemokines by tyrosine kinase MER/NYK in prostate cancer cells. Cancer Res 64: 7311-7320.
59. Wu X, Liu X, Koul S, Lee CY, Zhang Z, Halmos B. 2014. AXL kinase as a novel target for cancer therapy. Oncotarget 5: 9546-9563.
60. Yamakuchi M, Ferlito M, Lowenstein CJ. 2008. miR-34a repression of SIRT1 regulates apoptosis. Proc Natl Acad Sci 105: 13421-13426.
61. Yan D, Zhou X, Chen X, Hu DN, Dong XD, Wang J, Lu F, Tu L, Qu J. 2009. MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through downregulation of c-Met. Invest Ophthalmol Vis Sci 50: 1559-1565.
62. Younger ST, Corey DR. 2011. Transcriptional gene silencing in mammalian cells by miRNA mimics that target gene promoters. Nucleic Acids Res 39: 5682-5691.